These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19570113)

  • 1. Resource utilisation and costs for the treatment of diabetes in the developed world: an economical burden that needs to be solved.
    Jendle JH
    Int J Clin Pract; 2009 Jul; 63(7):980-2. PubMed ID: 19570113
    [No Abstract]   [Full Text] [Related]  

  • 2. Improving diabetes care in resource-poor countries: challenges and opportunities.
    Atkinson MA; Ogle GD
    Lancet Diabetes Endocrinol; 2013 Dec; 1(4):268-70. PubMed ID: 24622408
    [No Abstract]   [Full Text] [Related]  

  • 3. The cost burden of diabetes mellitus: the evidence from Germany--the CoDiM study.
    Köster I; von Ferber L; Ihle P; Schubert I; Hauner H
    Diabetologia; 2006 Jul; 49(7):1498-504. PubMed ID: 16752168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable cardiovascular risk factor profile is associated with lower healthcare expenditure and resource utilization among adults with diabetes mellitus free of established cardiovascular disease: 2012 Medical Expenditure Panel Survey (MEPS).
    Feldman DI; Valero-Elizondo J; Salami JA; Rana JS; Ogunmoroti O; Osondu CU; Spatz ES; Virani SS; Blankstein R; Blaha MJ; Veledar E; Nasir K
    Atherosclerosis; 2017 Mar; 258():79-83. PubMed ID: 28214425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes--inpatient utilisation, costs and data validity. Dunedin 1985-9.
    Phillips DE; Mann JI
    N Z Med J; 1992 Aug; 105(939):313-5. PubMed ID: 1501816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resource utilisation and health care costs in patients diagnosed with fibromyalgia in Spain.
    Rivera J; Rejas J; Esteve-Vives J; Vallejo MA;
    Clin Exp Rheumatol; 2009; 27(5 Suppl 56):S39-45. PubMed ID: 20074438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community household income and resource utilization for common inpatient pediatric conditions.
    Fieldston ES; Zaniletti I; Hall M; Colvin JD; Gottlieb L; Macy ML; Alpern ER; Morse RB; Hain PD; Sills MR; Frank G; Shah SS
    Pediatrics; 2013 Dec; 132(6):e1592-601. PubMed ID: 24276839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Economic cost of treating the patient with asthma in Spain: the AsmaCost study].
    Martínez-Moragón E; Serra-Batllés J; De Diego A; Palop M; Casan P; Rubio-Terrés C; Pellicer C;
    Arch Bronconeumol; 2009 Oct; 45(10):481-6. PubMed ID: 19525051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resource utilisation and cost of ankylosing spondylitis in Brazil.
    Torres TM; Ferraz MB; Ciconelli RM
    Clin Exp Rheumatol; 2010; 28(4):490-7. PubMed ID: 20810034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey.
    Willis WD; Diago-Cabezudo JI; Madec-Hily A; Aslam A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):123-30. PubMed ID: 23402452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes care and the White Paper--will it work for patients?
    Keen H; Bending J
    J R Coll Physicians Lond; 1989 Oct; 23(4):210-1. PubMed ID: 2585361
    [No Abstract]   [Full Text] [Related]  

  • 12. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
    Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
    Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
    J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs.
    Hex N; Bartlett C; Wright D; Taylor M; Varley D
    Diabet Med; 2012 Jul; 29(7):855-62. PubMed ID: 22537247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding Paramedicine in the Community (EPIC): study protocol for a randomized controlled trial.
    Drennan IR; Dainty KN; Hoogeveen P; Atzema CL; Barrette N; Hawker G; Hoch JS; Isaranuwatchai W; Philpott J; Spearen C; Tavares W; Turner L; Farrell M; Filosa T; Kane J; Kiss A; Morrison LJ
    Trials; 2014 Dec; 15():473. PubMed ID: 25467772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study.
    Bommer C; Heesemann E; Sagalova V; Manne-Goehler J; Atun R; Bärnighausen T; Vollmer S
    Lancet Diabetes Endocrinol; 2017 Jun; 5(6):423-430. PubMed ID: 28456416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The public health burden of diabetes and the reality of limits.
    Vinicor F
    Diabetes Care; 1998 Dec; 21 Suppl 3():C15-8. PubMed ID: 9850481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherpy. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study.
    Jönsson L; Justo N; Musayev A; Krishna A; Burke T; Pellissier J; Judson I; Staddon A; Blay JY
    Eur J Cancer Care (Engl); 2016 May; 25(3):466-77. PubMed ID: 25923192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective.
    Chevat C; Peña BM; Al MJ; Rutten FF
    Pharmacoeconomics; 2001; 19 Suppl 1():17-32. PubMed ID: 11280103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.
    Rosery H; Bergemann R; Maxion-Bergemann S
    Pharmacoeconomics; 2005; 23(3):243-57. PubMed ID: 15836006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.